Amgen to Review Business with Analysts

Aside from Dmab, the company will give the first comprehensive review of its pipeline in at least two years.

"While we do not expect Amgen to present any late-breaking Phase III data or unveil any novel late-stage drug candidates, we do believe the company's pipeline features many interesting Phase I, II, and III candidates, many of which have been overlooked in light of the focus on denosumab," the Cowen analysts wrote. The firm has an outperform rating on the stock.

According to Deutsche Bank's buy-side survey, 52% of respondents believe the meeting will be a positive event for the stock, while 5% think it will be negative.

"While we lack conviction on how the meeting will impact Amgen's stock price, we believe a solid core business coupled with dmab sales in oncology and osteoporosis will allow Amgen to post double-digit EPS growth and outperform the market by 20%+ over the next 12 months," wrote the Cowen analysts.

Amgen recently reined in research and development expenses for the year, and upped its adjusted profit guidance to a range of $4.45 to $4.55, from $4.25 to $4.45. The company also increased its revenue guidance to $14.9 billion to $15.2 billion, from $14.6 billion to $14.9 billion.

Expectations for Amgen have gone up as well. For the full year, the Street, on average, is now looking for $4.55 a share, on revenue of $15 billion, according to Thomson Reuters. Analysts had expected a profit of $4.38 a share and revenue of $14.82 billion prior to third-quarter earnings.